Trial Profile
A Multi-Country Retrospective Chart Review Study Assessing Treatment Characteristics and Deep Molecular Response in Chronic Phase–Chronic Myeloid Leukemia (CP-CML) Patients Treated with Second-Line Nilotinib or Dasatinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 May 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 26 Aug 2018 Results presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
- 22 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.